Association Use of Bisphosphonates with Risk of Breast Cancer: A Meta-Analysis

Table 1

Baseline characteristics of the studies included in the meta-analysis.

Study (year)	Nation	Study design	Period	Study database	Age (y), average (range or SD)	Menopausal status	No. of cases	No. of participants	Prevalence of breast cancer (%)
Cardwell (2011) [6]	UK	Cohort	1996-2006	GPRD	70 (11.4)	Pre- & post-	870	68098	1.28%
Chiang (2012) [7]	Taiwan	Cohort	1998-2009	NHIRD	73.5 (8.4)	Post-	209	27903	0.75%
Chlebowski (2010) [8]	USA	Cohort	1993-1998	WHI	NA (50-79)	Post-	6276	154768	4.06%
Fournier (2017) [9]	France	Cohort	2004-2011	E3N	62.8 (6.4)	Post-	2407	64438	3.73%
Hue (2014) [10]	USA	Cohort	1993-2006	FIT & HORIZON-PFT	70.6 (5.8)	Post-	165	13774	1.2%
Lee (2012) [11]	Taiwan	Cohort	1996-2009	NHI	NA (≥65)	Pre- & post-	65	18499	0.35%
Monsees (2011) [12]	USA	Case-control	1990-2007	SEER	NA (40-79)	Pre- & post-	351	1013	NA
Newcomb (2010) [13]	USA	Case-control	2003-2006	WMCR	54.2 (8.9)	Pre- & post-	2936	5911	NA
Rennert (2010) [14]	Israel	Case-control	2000-2006	CHS	63.6 (NA)	Post-	1832	4039	NA
Vestergaard (2011) [16]	Denmark	Cohort	1996-2006	DPB	71.1 (10.7)	Pre- & post-	4349	342651	1.27%
Vinogradova (2013) [15]	UK	Case-control	1997-2011	QResearch & CPRD	69.4 (9.8)	Pre- & post-	49933	282713	NA

Abbreviations: CHS: Clalit Health Service; CPRD: Clinical Practice Research Datalink; SEER: Surveillance, Epidemiology, and End Results; WMCR: Wisconsin Mandatory Cancer Registry; DPB: Danish population base; GPRD: General Practice Research Database; NHIRD: National Health Insurance Research Database; WHI: Women’s Health Initiative; E3N: Etude Epidémiologique Auprès de Femmes de la Mutuelle Générale de l'Education Nationale; FIT: Fracture Intervention Trial; HORIZON-PFT: Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly-Pivotal Fracture Trial; NHI: National Health Insurance; NA: not available; SD: standard deviation.